ArticleNeurology and therapy2025
Short-Term Outcomes and Immunologic Mechanisms of Adrenocorticotropic Hormone in Infantile Epileptic Spasm Syndrome: A Multicenter Prospective Trial in Southern China.
Article in Neurology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Validated LC-MS/MS Methods for Quantification of AC02 and Porcine ACTHPharmaceuticals (Basel, Switzerland) · 2026Article
- Electrophysiological readout of ACTH-related neuroendocrine-immunomodulatory treatment response in infantile epileptic spasms syndrome: suppression of scalp ripple propagation networks.Frontiers in immunology · 2026Article
- HMGB1-TLR4 signaling-mediated neuroinflammation contributes to the pathogenesis of infantile epileptic spasms syndrome in rats.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdrenocorticotropic hormone (ACTH) is a first-line drug and standard therapy in infantile epileptic spasm syndrome (IESS) with different response rates. The mechanism of ACTH for treatment of IESS remains incompletely understood. This study aimed to evaluate short-term outcomes and immunologic mechanisms of ACTH in treating pediatric patients with IESS.
methodsA multicenter prospective trial of pediatric patients with IESS treated with ACTH over 2 weeks was performed. Short-term responders were defined as those with resolution of epileptic spasms and hypsarrhythmia (if present) at day 14 without epileptic spasm recurrence over 30 days after ACTH therapy, while non-responders included those with persistent spasms or hypsarrhythmia after treatment, or recurrence within 30 days. The risk factors for short-term efficacy were analyzed. The receiver operating characteristic (ROC) curve analysis was adopted to reveal the optimal critical value of peripheral blood lymphocyte subpopulations before ACTH treatment.
resultsAmong 151 included pediatric patients, 44 (29.1%) were short-term responders. The presence of hypsarrhythmia on pre-therapy electroencephalogram (EEG) was a risk factor for the short-term efficacy (p = 0.029). A total of 81 patients accepted lymphocyte subpopulation investigation. The short-term responder group had a lower percentage of CD3
conclusionAbout 30% children with IESS were short-term responders to ACTH therapy. The presence of hypsarrhythmia on the pre-therapy EEG was a risk factor for short-term efficacy of ACTH administration. The CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.